Author:
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 854

Get Book Here

Book Description

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN: 9283212894
Category : Medical
Languages : en
Pages : 642

Get Book Here

Book Description
This eighty-ninth volume of the IARC Monographs is the third and last of a series on tobacco-related agents. Volume 83 reported on the carcinogenicity of tobacco smoke and involuntary smoking (second-hand smoke or environmental tobacco smoke) (IARC 2004a). Volume 85 summarized the evidence on the carcinogenic risk of chewing betel quid with and without tobacco (IARC 2004b). That volume explored the variety of products chewed in South Asia and other parts of the word that contain areca nut in combination with other ingredients, often including tobacco. In this eighty-ninth volume, the carcinogenic risks associated with the use of smokeless tobacco, including chewing tobacco and snuff, are considered in a first monograph. The second monograph reviews some tobacco-specific nitrosamines. These agents were evaluated earlier in Volume 37 of the Monographs (IARC 1985) and information gathered since that time has been summarized and evaluated.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN: 9283212797
Category : Health & Fitness
Languages : en
Pages : 774

Get Book Here

Book Description
This publication represents the views and expert opinions of an IARC Working Group which met in Lyon, 10-17 October 2000.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Meeting
Publisher: World Health Organization
ISBN: 9283212908
Category : Medical
Languages : en
Pages : 690

Get Book Here

Book Description
This ninetieth volume of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humansconsiders human papillomaviruses (HPVs) which were evaluated by a previous Working Group (IARC, 1995). The monograph in the present volume incorporates new data that have become available during the past decade. HPVs represent the most common infectious agents that are transmitted sexually throughout the world; the major risk factors are behaviors associated with sexual activity. Although most infections are asymptomatic and are cleared within a period of 2 years, genital HPV infection can lead to clinical disease, including anogenital warts, cervical neoplasia, cervical cancer and other anogenital cancers. The risk for persistence of infection and progression of the more than 40 genital HPV types to grade 3 cervical intraepithelial neoplasia (CIN3) and cancer differs widely. Persistent infection with carcinogenic HPVs occurs in virtually all cases of cervical cancer. Previous evaluations of HPVs have classified types 16 and 18 as carcinogenic to humans (group 1), types 31 and 33 as probably carcinogenic to humans (Group 2A) and some types other than 16, 18, 31 and 33 as possibly carcinogenic to humans (Group 2B). At that time, the evaluation of types 16 and 18 was based on the strong association between infection with these HPVs and cervical cancer. For types 31 and 33, the association was less strong. The new epidemiological data reviewed in the present volume strongly support and further confirm the previous evaluation of types 16 and 18, and provide new evidence for other HPVs. This information, which includes strong evidence of carcinogenicity at sites other than the cervix, supports new evaluations for several other HPV types in addition to those mentioned above. Since the Working Group was convened in 2005, important innovations in HPV prophylaxis have occurred and these needed to be included in this volume. To date two prophylactic vaccines have been developed and used in large multicentric trials. This prophylactic vaccination is expected to reduce the incidence of HPV-related genital diseases. However, the benefits of prophylactic vaccines in a broad public health perspective will be achieved only if such vaccines can be provided to those groups of women for whom access to cervical cancer screening services is most problematic. Therefore, the development of second-generation vaccines that are expected to be cheaper, easier to deliver and to provide T-cell response against pre-existing HPV infections is highly desirable.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN: 9283212770
Category : Medical
Languages : en
Pages : 574

Get Book Here

Book Description
This publication represents the views and expert opinion of an IARC Working Group which met in Lyon, 15-22 February 2000.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN: 9283212800
Category : Medical
Languages : en
Pages : 446

Get Book Here

Book Description
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 19-26 June 2001.

Author: Kirk T. Kitchin
Publisher: CRC Press
ISBN: 1000105466
Category : Science
Languages : en
Pages : 918

Get Book Here

Book Description
Offers comprehensive coverage of currently available cancer predictors, the most recent research on carcinogenicity, and the design and interpretation of carcinogenicity experiments. Presents mouse, rat, and human carcinogenicity data for the liver, kidney, breast, cervix, prostate, hematopoietic system, colon, skin, urinary bladder, mouth, stomach, thyroid, and pancreas.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN: 9283212827
Category : Medical
Languages : en
Pages : 602

Get Book Here

Book Description
This publication represents the views and expert opinions of an IARC Working Group which met in Lyon, 12-19 February 2002.

Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: IARC
ISBN: 9789283212850
Category : Health & Fitness
Languages : en
Pages : 354

Get Book Here

Book Description
A working group of sixteen experts from seven countries re-evaluated the evidence of the carcinogenicity of betel-quid and areca-nut chewing and some areca-nut related nitrosamines. Betel-quid and areca-nut chewing are widely practised in many parts of Asia and in Asian-migrant communities elsewhere in the world. There are hundreds of millions of users worldwide. They evaluated betel quid with tobacco as carcinogenic to humans (Group 1) on the basis of sufficient evidence of an increased risk of cancer of the oral cavity, pharynx and oesophagus. The working group reviewed epidemiological studies of human cancer, mainly studies from India, Pakistan and Taiwan (China). Studies on betel quid with tobacco and areca nut with tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. The working group also evaluated betel quid without tobacco as carcinogenic to humans (Group 1), on the basis of sufficient evidence of an increased risk of oral cancer. Studies on betel quid without tobacco and areca nut without tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. Areca nut, a common ingredient of betel quid and many different chewing preparations, including those available commercially, has been observed to cause oral submucous fibrosis

Author:
Publisher:
ISBN:
Category : Carcinogenesis
Languages : en
Pages : 692

Get Book Here

Book Description